Pancreatic Neuroendocrine Tumors: Update on the New World Health Organization Classification

Détails

ID Serval
serval:BIB_B91C60614EA7
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Pancreatic Neuroendocrine Tumors: Update on the New World Health Organization Classification
Périodique
AJSP: Reviews & Reports
Auteur(s)
Klöppel G., Klimstra DS, Hruban RH, Adsay V., Capella C., Couvelard A., Komminoth P., La Rosa S., Ohike N., Osamura RY
Collaborateur(s)
Perren A, Scoazec JY, Rindi G
ISSN
2381-5949
ISSN-L
2381-5949
Statut éditorial
Publié
Date de publication
25/09/2017
Peer-reviewed
Oui
Volume
22
Numéro
5
Pages
233–239
Langue
anglais
Résumé
The first classification of the pancreatic neuroendocrine neoplasms (PanNENs) that characterized the individual tumor by criteria with prognostic significance appeared in 1995. These criteria included a distinction by site and size, by degree of histological differentiation (well vs poor), by function (with and without hormonal syndrome), by angioinvasion, and by metastatic spread. The subsequently developed World Health Organization classifications in 2000, 2004, and 2010 largely followed this concept, but added proliferative activity as the best criterion reflecting tumor growth. In 2010, the classification combined histological differentiation with stratification into 3 tiers of proliferative activity, mainly using Ki67 as the most reliable measure of proliferation. The predictive value of this classification and grading system that was soon accompanied by an adequate TNM staging system has proved to be so excellent that all major treatment options of PanNENs, as well as extrapancreatic NENs, have been currently based on this classification. The new World Health Organization 2017 classification is a refinement of the previous version. Its main change is the introduction of a “pancreatic neuroendocrine tumor grade 3” category to recognize grade-discordant pancreatic neuroendocrine tumors and distinguish them from pancreatic neuroendocrine carcinomas, which are defined by their poorly differentiated nature. There is increasing evidence that this phenotypical classification of PanNENs allows a targeted molecular analysis, which is going to broaden our understanding of the tumors' biology.
Mots-clé
definition, grading, pancreatic neuroendocrine neoplasms, WHO 2017 classification
Web of science
Création de la notice
25/09/2017 11:18
Dernière modification de la notice
20/08/2019 15:27
Données d'usage